| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Regorafenib |
| Brand | Stivarga® |
| Indication | For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. |
| Assessment Process | |
| Rapid review commissioned | 12/09/2013 |
| Rapid review completed | 02/10/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 14/02/2014 |
| NCPE assessment completed | 30/06/2014 |
| NCPE assessment outcome | Reimbursement not Recommended |
The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.
Following discussions between the HSE and the company, regorafenib is now reimbursed under a patient access scheme.
